Diaceutics (LON:DXRX) Price Target Cut to GBX 185 by Analysts at Royal Bank Of Canada

Diaceutics (LON:DXRX - Free Report) had its price objective reduced by Royal Bank Of Canada from GBX 195 ($2.63) to GBX 185 ($2.49) in a report issued on Thursday, Marketbeat.com reports. They currently have an outperform rating on the stock.

Diaceutics Stock Up 2.1%

Shares of LON:DXRX traded up GBX 2.50 ($0.03) during trading on Thursday, hitting GBX 119 ($1.60). The stock had a trading volume of 12,197 shares, compared to its average volume of 125,377. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39. The company has a market capitalization of £100.43 million, a PE ratio of -35.29 and a beta of 0.58. The firm's fifty day moving average is GBX 124.79 and its 200 day moving average is GBX 128.63. Diaceutics has a 12 month low of GBX 106 ($1.43) and a 12 month high of GBX 151 ($2.04).

Diaceutics (LON:DXRX - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported GBX (2.02) (($0.03)) EPS for the quarter. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%. Analysts anticipate that Diaceutics will post 1.0107919 EPS for the current fiscal year.

Insider Activity at Diaceutics

In other Diaceutics news, insider Peter Keeling sold 500,000 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of GBX 126 ($1.70), for a total transaction of £630,000 ($849,629.13). 34.30% of the stock is owned by insiders.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.